Skip to main content
Premium Trial:

Request an Annual Quote

MDxHealth, LifeLabs Ink Distribution Agreement for Prostate Cancer Assay

This story has been updated to correct the type of biomarker used in MDxHealth's SelectMDx assay.

NEW YORK (GenomeWeb) – Belgian diagnostic firm MDxHealth announced today that it has signed a distribution agreement with LifeLabs to offer MDxHealth's SelectMDx assay in Canada.

Toronto-based LifeLabs will serve as the exclusive distributor in Canada for the noninvasive liquid biopsy assay, which is a urine-based assay that measures the expression of two mRNA cancer-related biomarkers to stratify patients who have signs of aggressive prostate cancer.

Researchers will test liquid biopsy samples in MDxHealth's clinical diagnostic laboratory in Irvine, California, while LifeLabs will reimburse MDxHealth for all testing services performed at the lab.

"By making this innovative, noninvasive test available, we are improving the quality of prostate cancer diagnosis and delivering healthier outcomes for Canadians," LifeLabs CEO Charles Brown said in a statement.

Financial details of the agreement were not disclosed.

"With over 25,000 US patients tested with SelectMDx to date, the test is clearly gaining momentum to become the standard of care in diagnosing patients with increased risk for aggressive prostate cancer," MDxHealth CEO Jan Groen said in a statement. "This partnership agreement with LifeLabs demonstrates our commitment to making SelectMDx widely available in North America and to offering a valuable and accurate alternative for patients at risk for prostate cancer."

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.